| Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients O Huillard, O Mir, M Peyromaure, C Tlemsani, J Giroux, ... British journal of cancer 108 (5), 1034-1041, 2013 | 256 | 2013 |
| CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study PR Benusiglio, D Malka, E Rouleau, A De Pauw, B Buecher, C Noguès, ... Journal of medical genetics 50 (7), 486-489, 2013 | 165 | 2013 |
| Posterior reversible encephalopathy syndrome induced by anti-VEGF agents C Tlemsani, O Mir, P Boudou-Rouquette, O Huillard, K Maley, S Ropert, ... Targeted oncology 6, 253-258, 2011 | 132 | 2011 |
| The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort D Damotte, S Warren, J Arrondeau, P Boudou-Rouquette, ... Journal of Translational Medicine 17, 1-10, 2019 | 101 | 2019 |
| SCLC-CellMiner: a resource for small cell lung cancer cell line genomics and pharmacology based on genomic signatures C Tlemsani, L Pongor, F Elloumi, L Girard, KE Huffman, N Roper, ... Cell reports 33 (3), 2020 | 93 | 2020 |
| Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study M Tiako Meyo, A Jouinot, E Giroux-Leprieur, E Fabre, M Wislez, M Alifano, ... Cancers 12 (2), 473, 2020 | 80 | 2020 |
| SETD2 and DNMT3A screen in the Sotos-like syndrome French cohort C Tlemsani, A Luscan, N Leulliot, E Bieth, A Afenjar, G Baujat, ... Journal of medical genetics 53 (11), 743-751, 2016 | 60 | 2016 |
| Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: a Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial S Pasquali, E Palmerini, V Quagliuolo, J Martin‐Broto, A Lopez‐Pousa, ... Cancer 128 (1), 85-93, 2022 | 54 | 2022 |
| Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair–targeted therapies C Tlemsani, N Takahashi, L Pongor, VN Rajapakse, M Tyagi, X Wen, ... Science translational medicine 13 (578), eabc7488, 2021 | 44 | 2021 |
| Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib C Tlemsani, O Huillard, J Arrondeau, P Boudou-Rouquette, A Cessot, ... Expert opinion on drug metabolism & toxicology 11 (5), 785-794, 2015 | 37 | 2015 |
| High prevalence of somatic oncogenic driver alterations in patients with NSCLC and Li-Fraumeni syndrome L Mezquita, M Jové, E Nadal, M Kfoury, T Morán, C Ricordel, M Dhooge, ... Journal of Thoracic Oncology 15 (7), 1232-1239, 2020 | 34 | 2020 |
| Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma B Rousseau, A Guillemin, C Duvoux, C Neuzillet, C Tlemsani, ... International Journal of Cancer 144 (4), 886-896, 2019 | 29 | 2019 |
| Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review P Boudou-Rouquette, C Tlemsani, B Blanchet, O Huillard, A Jouinot, ... Expert opinion on drug metabolism & toxicology 12 (12), 1433-1444, 2016 | 29 | 2016 |
| Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old F Bigot, P Boudou-Rouquette, J Arrondeau, A Thomas-Schoemann, ... Investigational new drugs 35, 242-246, 2017 | 27 | 2017 |
| Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity M Bretagne, A Jouinot, JP Durand, O Huillard, P Boudou Rouquette, ... Cancer Chemotherapy and Pharmacology 80, 45-53, 2017 | 25 | 2017 |
| Hereditary diffuse gastric cancer syndrome: improved performances of the 2015 testing criteria for the identification of probands with a CDH1 germline mutation PR Benusiglio, C Colas, E Rouleau, N Uhrhammer, P Romero, ... Journal of Medical Genetics 52 (8), 563-565, 2015 | 24 | 2015 |
| Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients A Jouinot, G Ulmann, C Vazeille, JP Durand, P Boudou-Rouquette, ... Clinical nutrition 39 (6), 1893-1899, 2020 | 23 | 2020 |
| Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options C Tlemsani, K Leroy, AP Gimenez-Roqueplo, A Mansuet-Lupo, ... Journal of Medical Genetics 57 (2), 104-108, 2020 | 20 | 2020 |
| Clinical and genomic characteristics of small cell lung cancer in never smokers: results from a retrospective multicenter cohort study A Thomas, I Mian, C Tlemsani, L Pongor, N Takahashi, K Maignan, ... Chest 158 (4), 1723-1733, 2020 | 19 | 2020 |
| Body composition in patients with radioactive iodine-refractory, advanced differentiated thyroid cancer treated with sorafenib or placebo: A retrospective analysis of the phase … O Huillard, A Jouinot, C Tlemsani, MS Brose, J Arrondeau, G Meinhardt, ... Thyroid 29 (12), 1820-1827, 2019 | 16 | 2019 |
